Login / Signup

A 'click' chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras.

Jasmine M CrossMegan E CoulsonJoshua P SmalleyWiktoria A PytelOzair IsmailJustin S TroryShaun M CowleyJames T Hodgkinson
Published in: RSC medicinal chemistry (2022)
Click chemistry was utilised to prepare a library of PROTACs based on entinostat a class I histone deacetylase (HDAC) inhibitor in clinical trials. A novel PROTAC JMC-137 was identified as a HDAC1/2 and HDAC3 degrader in HCT116 cells. However, potency was compromised compared to previously identified class I HDAC PROTACs highlighting the importance in the choice of HDAC ligand, functional group for linker attachment and positioning in PROTAC design.
Keyphrases
  • histone deacetylase
  • clinical trial
  • cell cycle arrest
  • multiple sclerosis
  • drug discovery
  • randomized controlled trial
  • ms ms
  • cancer therapy
  • open label
  • study protocol
  • endoplasmic reticulum stress
  • phase ii